These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22237846)

  • 1. Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.
    Arrichiello C; Aloj L; Mormile M; D'Ambrosio L; Frigeri F; Caracò C; Arcamone M; De Martinis F; Pinto A; Lastoria S
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):956-66. PubMed ID: 22237846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
    Cremonesi M; Ferrari M; Grana CM; Vanazzi A; Stabin M; Bartolomei M; Papi S; Prisco G; Ferrucci PF; Martinelli G; Paganelli G
    J Nucl Med; 2007 Nov; 48(11):1871-9. PubMed ID: 17978355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MIRD dose estimate report No. 20: radiation absorbed-dose estimates for 111In- and 90Y-ibritumomab tiuxetan.
    Fisher DR; Shen S; Meredith RF
    J Nucl Med; 2009 Apr; 50(4):644-52. PubMed ID: 19289440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
    Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
    Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.
    Rizvi SN; Visser OJ; Vosjan MJ; van Lingen A; Hoekstra OS; Zijlstra JM; Huijgens PC; van Dongen GA; Lubberink M
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):512-20. PubMed ID: 22218876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
    Chiesa C; Botta F; Coliva A; Maccauro M; Devizzi L; Guidetti A; Carlo-Stella C; Seregni E; Gianni MA; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1745-57. PubMed ID: 19455328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (
    Wahl RL; Frey EC; Jacene HA; Kahl BS; Piantadosi S; Bianco JA; Hammes RJ; Jung M; Kasecamp W; He B; Sgouros G; Flinn IW; Swinnen LJ
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
    Assié K; Dieudonné A; Gardin I; Buvat I; Tilly H; Vera P
    Cancer Biother Radiopharm; 2008 Feb; 23(1):53-64. PubMed ID: 18298329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
    Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
    J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
    Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistribution.
    Aricò D; Grana CM; Vanazzi A; Ferrari M; Mallia A; Sansovini M; Martinelli G; Paganelli G; Cremonesi M
    Cancer Biother Radiopharm; 2009 Apr; 24(2):271-5. PubMed ID: 19409050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.
    Ferrer L; Malek E; Bodet-Milin C; Legouill S; Prangère T; Robu D; Jeans S; Tipping J; Huglo D; Carpentier P; Illidge T; Kraeber-Boderé F; Morschhauser F; Bardiès M
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):529-37. PubMed ID: 23358406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
    Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
    J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
    Delaloye AB; Antonescu C; Louton T; Kuhlmann J; Hagenbeek A
    J Nucl Med; 2009 Nov; 50(11):1837-43. PubMed ID: 19837764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Wiseman GA; White CA; Sparks RB; Erwin WD; Podoloff DA; Lamonica D; Bartlett NL; Parker JA; Dunn WL; Spies SM; Belanger R; Witzig TE; Leigh BR
    Crit Rev Oncol Hematol; 2001; 39(1-2):181-94. PubMed ID: 11418315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.